-
Tocilizumab vs. Sarilumab Among Adults Hospitalized Due to COVID-19: A Federated Comparative Effectiveness Study Across England and Scotland Under the Target Trial Emulation Framework
Sep 9, 2025, 16:22 PM -
The Clinical Impact of Screening Blood Donations for Hepatitis E Virus in Catalonia
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Nemolizumab in the Treatment of Patients With Moderate-to-Severe Prurigo Nodularis in Italy
Sep 9, 2025, 16:22 PM -
Bimekizumab Led to Sustained Improvements in Health-Related Quality of Life and Work Productivity in Patients With Axial Spondyloarthritis: 3-Year Results From Two Phase 3 Studies
Sep 9, 2025, 16:22 PM -
Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review
Sep 9, 2025, 16:22 PM -
Evaluating High-Cost Gene Therapies for Noncancer Conditions: Insights From NICE's Standard Appraisal Process
Sep 9, 2025, 16:22 PM -
Cost Effectiveness and Budget Impact Analysis of Benralizumab for Treating Severe Uncontrolled Eosinophilic Asthma in Egypt
Sep 9, 2025, 16:22 PM -
Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis
Sep 9, 2025, 16:22 PM -
Budget Impact Minimization Approaches Used Across Europe, Brazil, and Japan in the Reimbursement of Obesity Medications
Sep 9, 2025, 16:22 PM -
Economic Evaluation of a Booster Dose of TDaP Vaccine to Adolescents in Spain
Sep 9, 2025, 16:22 PM -
Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis
Sep 9, 2025, 16:22 PM -
Optimal Utilization of Robotic-Assisted Surgery in the NHS: A System-Level Economic Evaluation Model
Sep 9, 2025, 16:22 PM -
Implementation and Outcomes of Managed Entry Agreements Across the Nordic Region
Sep 9, 2025, 16:22 PM -
Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada
Sep 9, 2025, 16:22 PM -
From Policy to Practice: Are Larger Member States Leading the Way for Joint Clinical Assessments?
Sep 9, 2025, 16:22 PM -
Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France
Sep 9, 2025, 16:22 PM -
Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025
Sep 9, 2025, 16:22 PM -
Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
Societal Impact Analysis of Introducing Elexacaftor Tezacaftor Ivacaftor (ELX TEZ IVA) in the Management of People With Cystic Fibrosis in Germany: A Paid and Unpaid Work Productivity Approach
Sep 9, 2025, 16:22 PM -
Early Adoption of New Combination Biologic Therapy Enabled by Enhanced Diagnostic Accuracy in Inflammatory Bowel Disease (IBD) Can Be a Budget-Neutral Approach: A Budget Impact Analysis in Italy
Sep 9, 2025, 16:22 PM
